Bioburden

Bioburden is the measurable count of viable (living) microorganisms, such as bacteria or fungi, present in a raw material or active pharmaceutical ingredient before final sterilization. On a lab report, bioburden testing functions as a preventive process-control check to confirm that upstream manufacturing steps were clean enough to proceed. This value is especially relevant for injectable products, where microbial contamination directly threatens patient safety. Because acceptance criteria depend on the product's intended use and manufacturing stage, there is no universal pass or fail limit for bioburden.

Bioburden measurement follows a defined lab sequence

The lab measures bioburden by extracting microbes from the sample and transferring them onto nutrient growth media for a seven-day incubation period. During this time, technicians observe whether the microorganisms multiply, reporting the final result as Colony Forming Units (CFU) per unit of volume or weight. For products with antimicrobial properties, a method suitability test must be completed first. This preliminary step ensures the sample does not artificially suppress microbial growth, which would otherwise produce a false-negative result and hide real contamination.

Bioburden differs from sterility, endotoxin, and chemical purity tests

• Bioburden is not a sterility test: It measures microbial levels before sterilization, while a sterility test confirms a finished product is completely microbe-free afterward.
• Bioburden differs from endotoxin testing: This test detects toxic molecules from dead bacteria that can survive sterilization, whereas bioburden counts living organisms.
• Bioburden evaluates biological contamination: A product could be 99.5% chemically pure but still carry unacceptable microbial levels.

Sources

1. [PDF] Pharmaceutical Microbiology Manual - FDA
2. Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients | FDA
3. Bioburden Method Suitability: A Practical Solution to Screening for ...
4. [PDF] Q 7 Good Manufacturing Practice for Active Pharmaceutical ... - EMA
5. FDA Sets Peptide Impurity Thresholds as Low as 0.10%, ...
6. [PDF] Q 6 B Specifications: Test Procedures and Acceptance Criteria for ...
8. The Biologics Revolution and Endotoxin Test Concerns
9. Bioburden Control: Testing, Definitions, and Best Practices
10. Bioburden testing​ and endotoxin testing — CMD
11. Q&A from European GMP Conference: "Bioburden
12. Bioburden vs. Bacterial Endotoxin Testing: Exploring Methods, Differences, and Laboratory Practices in Medical Devices
13. 〈1119.1〉 Bioburden Test
14. Bioburden Testing - Rocker Scientific
15. Bioburden Testing: Purpose, Procedure, and Accepted Level
16. What is the Difference Between Bioburden and Endotoxin Test?
17. Difference between sterility, bioburden, pyrogen, and bacterial ...
18. Changes to Regulatory Policy in Bioburden Testing